DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.
Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...
A long-term investor mindset will help make money, focus on new products at pharma companies draws to a close, Meta’s latest shift befuddles Indian fact-checkers, and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback